KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Enterprise Value (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Enterprise Value data on record, last reported at -$204.7 million in Q4 2025.

  • For Q4 2025, Enterprise Value fell 458.52% year-over-year to -$204.7 million; the TTM value through Dec 2025 reached -$204.7 million, down 458.52%, while the annual FY2025 figure was -$204.7 million, 458.52% down from the prior year.
  • Enterprise Value reached -$204.7 million in Q4 2025 per AMRX's latest filing, down from $33.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at $57.1 million in Q4 2024 and bottomed at -$439.0 million in Q1 2021.
  • Average Enterprise Value over 5 years is -$64.3 million, with a median of -$9.9 million recorded in 2024.
  • Peak YoY movement for Enterprise Value: tumbled 2677.25% in 2021, then surged 2574.1% in 2025.
  • A 5-year view of Enterprise Value shows it stood at $8.0 million in 2021, then surged by 97.26% to $15.7 million in 2022, then plummeted by 420.1% to -$50.2 million in 2023, then soared by 213.65% to $57.1 million in 2024, then plummeted by 458.52% to -$204.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$204.7 million in Q4 2025, $33.1 million in Q3 2025, and -$5.7 million in Q2 2025.